Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

KRAS is one of the most commonly mutated oncogenes in lung, colorectal, and pancreatic cancers. Recent clinical trials directly targeting KRAS G12C presented encouraging results for a large population of non–small cell lung cancer (NSCLC), but resistance to treatment is a concern. Continued explorat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Catherine, Jiang, Ziyue Karen, Planken, Simon, Manzuk, Lisa K., Ortiz, Roberto, Hall, Michael, Noorbehesht, Kavon, Ram, Sripad, Affolter, Timothy, Troche, Gabriel E., Ihle, Nathan T., Johnson, Theodore, Ahn, Youngwook, Kraus, Manfred, Giddabasappa, Anand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Models and Technologies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320479/
https://www.ncbi.nlm.nih.gov/pubmed/37186518
http://dx.doi.org/10.1158/1535-7163.MCT-22-0810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320479/
https://www.ncbi.nlm.nih.gov/pubmed/37186518
http://dx.doi.org/10.1158/1535-7163.MCT-22-0810

Ejemplares similares